Original Research

DOI: 10.4244/EIJ-D-23-00823

Outcomes and performance of the ACURATE neo2 transcatheter heart valve in clinical practice: one-year results of the ACURATE neo2 PMCF Study

Won-Keun Kim1, MD; Helge Möllmann2, MD; Matteo Montorfano3, MD; Julia Ellert-Gregersen4, MD; Tanja K. Rudolph5, MD; Nicolas M. Van Mieghem6, MD, PhD; Michael Hilker7, MD; Ignacio Amat-Santos8, MD, PhD; Christian Juhl Terkelsen9, MD, DMSc; Anna Sonia Petronio10, MD; Pieter Stella11, MD, PhD; Matthias Götberg12, MD, PhD; Andreas Rück13, MD, PhD; A. Markus Kasel14, MD; Ramiro Trillo15, MD; Clare Appleby16, MBChB, PhD; Marco Barbanti17, MD; Philipp Blanke18, MD; Federico M. Asch19, MD; Rodrigo Modolo20, MD, PhD; Dominic J. Allocco20, MD; Corrado Tamburino21, MD, PhD

Abstract

Background: Transcatheter aortic valve implantation is an effective treatment for patients with aortic stenosis; however, complications related to paravalvular leakage (PVL) persist, including increased risk of mortality, cardiovascular mortality, and rehospitalisation.

Aims: We sought to evaluate the clinical outcomes and valve performance at 1 year in patients with severe aortic stenosis treated with the ACURATE neo2 valve in a post-market clinical setting.

Methods: Valve Academic Research Consortium-2 safety events were assessed up to 1 year. Independent core laboratories evaluated echocardiographic measures of valve performance and hypoattenuated leaflet thickening (HALT; as measured by four-dimensional computed tomography).

Results: The study enrolled 250 patients (64% female; mean age: 81 years; baseline Society of Thoracic Surgeons risk score: 2.9±2.0%); 246 patients were implanted with ACURATE neo2. All-cause mortality was 0.8% at 30 days and 5.1% at 1 year. The 1-year rates for stroke and disabling stroke were 3.0% and 1.3%, respectively. Overall, HALT of >50% leaflet involvement of at least one leaflet was present in 9% of patients at 30 days and in 12% of patients at 1 year. No association was observed between the presence of HALT and 1-year clinical or haemodynamic outcomes. Early haemodynamic improvements were maintained up to 1 year (mean aortic valve gradient: 47.6±14.5 mmHg at baseline, 7.6±3.2 mmHg at 1 year; mean aortic valve area: 0.7±0.2 cm2 at baseline, 1.7±0.4 cm2 at 1 year). At 1 year, 99% of patients had mild or no/trace PVL (<1% had moderate PVL; no patient had severe PVL).

Conclusions: The study outcomes confirm favourable performance and safety up to 1 year in patients treated with ACURATE neo2 in routine clinical practice. (ClinicalTrials.gov: NCT04655248)

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 1
Jan 1, 2024
Volume 20 Number 1
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-23-00058 Jan 1, 2024
Real-world evidence with the ACURATE neo2: a prelude to the ACURATE IDE trial
Windecker S and Tomii D
free

Research Correspondence

10.4244/EIJ-D-23-00852 Aug 5, 2024
Five-year outcomes of transcatheter aortic valve implantation with the ACURATE neo2 valve system
Möllmann H et al

Editorial

10.4244/EIJ-E-22-00050 Jan 23, 2023
Rocky II, Rambo II, and the ACURATE neo2
Serruys PW et al
free

Research Correspondence

10.4244/EIJ-D-23-01018 Jun 17, 2024
Midterm durability of the ACURATE transcatheter aortic valve implantation system based on VARC-3 definitions
Rück A et al
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved